Mirati Therapeutics, Inc. Common Stock
MRTX
MRTX was delisted on the 22nd of January, 2024.
172 hedge funds and large institutions have $4.48B invested in Mirati Therapeutics, Inc. Common Stock in 2019 Q2 according to their latest regulatory filings, with 46 funds opening new positions, 65 increasing their positions, 40 reducing their positions, and 30 closing their positions.
98% more call options, than puts
Call options by funds: $214M | Put options by funds: $108M
86% more funds holding in top 10
Funds holding in top 10: 7 → 13 (+6)
63% more repeat investments, than reductions
Existing positions increased: 65 | Existing positions reduced: 40
53% more first-time investments, than exits
New positions opened: 46 | Existing positions closed: 30
51% more capital invested
Capital invested by funds: $2.96B → $4.48B (+$1.52B)
8% more funds holding
Funds holding: 159 → 172 (+13)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
+$135M |
| 2 |
Sands Capital Management
Arlington,
Virginia
|
+$107M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$62.5M |
| 4 |
Invesco
Atlanta,
Georgia
|
+$59.9M |
| 5 |
Renaissance Technologies
New York
|
+$31M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$131M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
-$31.3M |
| 3 |
Janus Henderson Group
London,
United Kingdom
|
-$27.8M |
| 4 |
State Street
Boston,
Massachusetts
|
-$21M |
| 5 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$19.8M |
MRTX Hedge Fund Activity: Q2 2019 in Review
172 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Mirati Therapeutics, Inc. Common Stock (MRTX) for Q2 2019, worth a combined $4.48B — up 51% from $2.96B a quarter earlier.
Buyers outnumbered sellers: 46 funds opened new MRTX positions and 30 closed out — a net gain of 16 holders — while 65 added to existing stakes and 40 trimmed.
The largest buyer was Perceptive Advisors, adding an estimated $135M. The largest seller was Fidelity Investments, cutting an estimated $131M.
- 172 institutional investors held Mirati Therapeutics, Inc. Common Stock (MRTX) as of Q2 2019, up from 159 in Q1 2019.
- Funds reported $4.48B of Mirati Therapeutics, Inc. Common Stock stock for Q2 2019, up 51% quarter-over-quarter.
- 46 funds opened new Mirati Therapeutics, Inc. Common Stock positions in Q2 2019 and 30 closed out, a net change of +16 holders.
- The largest Mirati Therapeutics, Inc. Common Stock buyer in Q2 2019 was Perceptive Advisors, an estimated $135M added.
- The largest Mirati Therapeutics, Inc. Common Stock seller in Q2 2019 was Fidelity Investments, an estimated $131M sold.
Based on aggregated 13F filings for Q2 2019.